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Summary
Highly purified, small dense splenic B cells from unstimulated mice showed increasedexpression
ofclassIImajorhistocompatibility complex(MHC) antigens and enhanced viabilitywhen cultured
with affinity-purified recombinant interleukin 10 (HIA0), compared with B cells cultured in
mediumalone. Theseresponseswereblockedbyamonoclonal antibody (mAb) specific for 11,10,
but not by an isotype-matched control antibody. IL10 did not upregulate the expression ofFce
receptors (CD23) or class I MHC antigens on small dense B cells or induce their replication
as monitored by [3H]thymidine incorporation. While these B cell-stimulatory properties ofIWO
are also mediated by ID4, the two cytokines appear to act independently in these assays; anti-
IL10 antibodies blocked1140 but not I14-mediated B cellviabilityenhancement, and viceversa.
Similarly, since IIr4 upregulates CD23 on small dense B cells, the inability of IIr10 to do so
argues against its acting via endogenously generated 114. Finally, IIA0 did not upregulate class
II MHC antigens on B cells from Xchromosome-linked immunodeficiency (XID) mice, while
the same cells showed normal upregulation ofclass II antigens in response to 11.4. This report
also extends our understanding of the relationship between IIA0 and the highly homologous
Epstein-Barrvirus (EBV)-encoded Barn HI fragment C rightward readingframeno. 1 (BCRFI)
protein. It haspreviously been shown thatBCRFIprotein exhibitsthe cytokine synthesis inhibitory
activity ofIL10. This report indicates that BCRFI protein alsoenhances invitroB cell viability,
but does not upregulate class II MHC antigens on B cells. One explanation for these data is
that 111,10contains atleast two functional epitopes, onlyoneofwhichhas beenconservedby EBV
Blymphocytescontribute to theimmuneresponse bytheir
production ofspecific antibodies in response to antigenic
stimuli. This process is regulated by a subset ofsoluble gly-
coproteins collectively termed cytokines (1-3). The precise
number ofcytokines involved and their modes ofaction re-
quirefurther clarification. 11,10 (originallydesignated cytokine
synthesis inhibitory factor [CSIF]l; 4) is a cytokine produced
by activated type 2 T helper (Th2) cells (4, 5) and B cells
(6, 7),whichhas thepropertyofsuppressingcytokineproduc-
tion by type 1 T helper (Thl)cells(4). Isolation ofthecDNA
for mouse RAO (8) revealed a striking homology between
' Abbreviations used in this paper: BCRFI, BamHI fragment C rightward
reading frame no. 1; CSIF, cytokine synthesis inhibitory factor; MTT,
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; SA,
streptavidin; Thl/Th2, type 1/type 2 T helper cells; XID, X chromo-
some-linked immunodeficiency.
this cytokine and a previously uncharacterized open reading
frame, designated BamHI fragment Crightwardreadingframe
no. 1 (BCRFI), in the EBVgenome. Subsequent expression
and testing ofthe protein encoded by BCRFI revealed that
this molecule also mediated suppression of Thl cytokine
production (9). Isolation ofIIAOgenomicclones (8) confirmed
the mammalian origin of this cytokine, and suggested viral
capture of a cellular gene that presumably conferred some
survival advantage on the virus.
In this report, we show that 11,10 is also a novel B cell
stimulatoryfactor, exerting atleast twoeffectson smalldense
splenicB cells fromunstimulated mice, namely upregulation
oftheir class II MHC antigens and enhancement oftheir in
vitro viability. X chromosome-linked immunodeficiency
(XID) B cells are unresponsive to the class II inducing ac-
tivity of IWO, suggesting a possible role for this cytokine
in the immunodeficiency of these animals.
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Mice.
￿
8-12-wk-old female BALE/cByJ, DBA/2J, and CBA/J
mice were obtained from TheJackson Laboratory (Bar Harbor, ME).
The XID gene-bearing (CBA/N x DBA/2J) male and theirnormal
female littermates were bred at the DNAX animal facility (DNAX
Research Institute ofMolecular and Cellular Biology, Palo Alto,
CA) from breeding pairs obtained from The Jackson Laboratory.
Anticytokine Antibodies.
￿
Hybridoma celllines producing rat IgM
anti-IIA0 antibody (SXCI) (10) or an irrelevant rat IgM isotype
control designatedJ5/D were expanded in serum-free medium, and
the accumulated antibody was purified to a single band on a
Coomassie blue-stained SDS-PAGE gel by two sequential 50% am-
monium sulfate precipitates. Both antibodies were used at 10-50
jug/ml. Anti-1164 antibody (11B11) (11) and an IgG1 isotype con-
trol (GL113) were used at 10 hg/ml.
Cytokines.
￿
Mouse rI1610 was expressed in Escherichia coli and
a$mity purified using the SXCI anti-11610 antibody (Castle, B. E.,
W Dang, R. Kastelein, and M. Howard, manuscript in prepara-
tion). Alternatively, mouserI1r10(8), human rII1610 (12), and BCRFI
(9) were expressed in COS7 cells. Mock supernatants from COS7
cells transfected with no cDNA or irrelevant cDNA were used as
negative controls. Natural 11610 derived from Con A-stimulated
D10 Th cells was purified as described elsewhere (4) and gener-
ously provided by M. W Bond (DNAX). For both 11,10 and
BCRFI, a unit of activity was defined as the amount of protein
per milliliter that produced 50% of saturating activity in the
cytokine synthesis inhibitoryassay(4). Murine rM4 wasexpressed
inE. colt as described byvan Kimmenade et al. (13) and was affinity
purified as described elsewhere (14). A unit of IIA activity was
defined as the amount of 1164 per milliliter that produced 50%
of saturating activity in the HT-2 cell proliferation assay (5).
B CellPreparation and Culture
￿
Small dense B cells from unstimu-
lated mouse spleens were purified as described previously (15).
Briefly, spleen cells were teased into complete RPMI (cRPMI) con-
taining 5% FCS (J.R. Scientific, Woodland, CA), 5 x 10-5 M
2-ME (Polysciences, Inc., Warrington, PA), 100 U/ml penicillin
and 100 fag/ml streptomycin (Irvine Scientific, Santa Ana, CA),
2 mM glutamine (J.R. Scientific), and 25 mM Hepes buffer (Ir-
vine Scientific). RBC were lysed using 0.83% ammonium chlo-
ride, pH 7.4. In some experiments adherent cells were removed
by incubating cells on petridishes (Falcon Labware, Oxnard, CA)
at 2 x 107 cells/ml, 10 ml/dish at 37°C for 1 h. T cells were sub-
sequently removed using two successive treatments ofanti-mouse
Thy-1.2 mAb (New England Nuclear, Boston, MA) and anti-L3T4
antibody (RL172.4 hybridoma, a gift from Dr. H. R. MacDonald,
Ludwig Institute, Epalinges, Switzerland) for 20 min at 4°C, fol-
lowed by complement (1:10 dilution of LowTox-Rabbit comple-
ment; Cedarlane Laboratory Ontario, Canada) for 30 min at 37°C.
Small dense B cells were then isolated by density centrifugation
using a discontinuous gradient composed of 75, 65, and 50% Per-
coll (Pharmacia Fine Chemicals, Uppsala, Sweden) at 2,500 x g
for 25 min, at 4°C. Cells collected from the interface between 65
and 75% Percoll solutions were shown to be small dense B cells
by several criteria (15, 16) and used in all subsequent experiments.
Small B cells were cultured with various cytokines at 1-2 x 105
cells/well in 100101 cRPMIin 96-well flat-bottomed culture plates
(3072; Falcon Labware).
Immunofluorescence Determination ofSurface Markers.
￿
Cultured
B cells were harvested from microtiter plates, washed, then incubated
at 1-2 x 105 cells/well for 30 min at 4°C with one of the fol-
lowing antibodies: biotinylated anti-I-A' (mouse IgG2a) at 2.5
,ug/ml, biotinylated anti-H-2Kk (mouse IgG2a) at 2.5,ug/ml, bio-
tinylated anti-huHLADR (mouse IgG2a) at 5 Kg/ml, or bio-
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tinylated anti-rat tc chain (MAR 18.5, mouse IgG2a) at 5 I~g/ml,
biotinylated anti-CD23 antibody (B3B4, rat IgG2a) at 5 wg/ml.
With the exception of anti-CD23 (17), which was obtained as a
gift from Dr. D. H. Conrad at Medical College ofVirginia, these
antibodieswere purchased from Becton Dickinson & Co. (Moun-
tain View, CA). All antibodieswere biotinylated in our laboratory
by standard methods. Cells were washed in 1-2 ml HBSS (Gibco
Laboratories, GrandIsland, NY) + 3% BSA (Sigma Chemical Co.,
St. Louis, MO) and subsequently incubated with streptavidin-PE
(SAPE) (Becton Dickinson & Co.) at 1:10 in HBSS + 3% BSA
for 30 min at 4°C. Stained cells were fixedin HBSS (Gibco labora-
tories) + 1% formaldehyde (JT Baker Chemical Co., Phillips-
burg, NJ) and analyzedwithin 3 d. The relative fluorescence inten-
sities ofindividualcells were measured using a FACScan analyzer
(Becton Dickinson & Co.). Dead cells and aggregated cells were
excluded based on their forward angle light scatter. In some ex-
periments, cells were not fixed and dead cells were discriminated
based on their forward angle light scatter and propidium iodide
uptake.
Measurement ofB Cell Viability or Proliferation.
￿
Cell viability was
estimated by either trypan blue exclusion (0.4% trypan blue stain
in 0.85% saline; Gibco Laboratories) or MTT [3-(4,5 dimethyl-
thiazol-2y1)-2,5-diphenyl tetrazoliumbromide] assay (18). The latter
assay involved culturing cells at 2 x 105 B cells/well for 3 d fol-
lowed by a 4-h pulse with 50 ng/ml MTT (Sigma Chemical Co.).
Thecolorimetric change, as measured on ELISA reader at 570-650
nm, is an index oftotalviable cells. DNA synthesis was measured
by the incorporation of tritiated thymidine after 4-h pulse with
1 p.Ci/well ['H]thymidine (NET027; New England Nuclear,
Boston, MA).
Results
ILIO Upregulates Expression of Class II MHC Antigens on
Small DenseB Cells. Highly purified small dense B cells from
unstimulated BALB/c mouse spleens were cultured for 20-24
h either with various dilutions of affinity-purified rI1r10 ex-
pressed in E. coli, 100 U/ml affinity-purified rIlr4 as a posi-
tive control, or medium alone. Fig. l A shows that both 11,4
and a saturating dose (200 U/ml) of IIr10 caused substantial
upregulation of B cell classII MHC antigen expression com-
paredwith B cellscultured in medium alone. B cellscultured
under the same three conditions showed no difference in back-
ground staining using any of several biotinylated isotype-
matched negative control antibodies [e.g., anti-huHLADR,
anti-H-2Kk, and MAR 18.5 (anti-rat K chain)] or after
preincubation of the cells with anti-Fc receptor antibody
(2.4G2)(data not shown). These data indicate that II*10 does
not increase nonspecific binding to B cells. Identical results
of increased class II antigen expression were obtained using
rI1r10 expressed in COS7.cells or highly purified natural M10
produced by activated D10 Th cells (data not shown). IIr10--
induced upregulation of class II antigen expression could be
totally inhibited by anti-IIA0 mAb (SXCI) but not by an
irrelevant isotype-matched control antibody (J5/D) (Fig. 1
B). The amount ofmurine IIr10 required for optimal induc-
tion of class II MHC antigens on B cells was comparable
with that needed for optimal suppression of cytokine syn-
thesis by Thl cells; -10--100 U/ml produced an optimal re-
sponse in each assay. Affinity-purified rIlrl0 did not upregu-
late expression of class I MHC antigens or CD23 on smalldense B cells (Fig. 2) . In fact, a small but detectable decrease
in class I MHC antigen expression was observed after cul-
ture of B cells with IIAO (Fig . 2) .
IMO Does Not Upregulate Class II Antigen Expression on
XID B Cells. While B cells from several normal strains of
mice (e.g., BALB/cByj, and DBA/2J) responded to IL10 by
upregulating class IIMHC antigen expression, small dense
splenicB cells from the immunodeficient XID mouse seemed
incapable of this response . As shown in Fig. 3, class II an-
tigen expression on XID splenic B cells from CBA/N x
DBA/2 male mice was upregulated after IL4 stimulation,
but was unaltered after culture with IL10. In contrast, the
normal control population of CBA/N x DBA/2 female
mouseB cells showed significant upregulation ofclass IIMHC
antigen expression after eitherHA or IIAO stimulation (Fig. 3) .
IMO Enhances In Vitro Viability of Small Dense B Cells.
Highly purified small denseB cells from unstimulatedBALB/c
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Figure 1 .
￿
Effect ofIIAO on class
IIMHC antigen expression on small
dense Blymphocytes from unstimu-
lated BALB/c mice . (A) Splenic B
cells were cultured for 22 h either
in medium alone, in medium sup-
plemented with 200 U/ml affinity-
purifiedE. coli-expressedmouse rll,
10, or in medium supplemented
with 100 U/mlpurified rI1r4 . Class
II MHC antigen expression was
evaluated using biotinylated anti-
I-Ad antibody plus SA-PE . (B)
Splenic B cells were cultured for
22 h with various concentrations of
affinity-purified E. coli-expressed
rI1.10 alone ("), in the presence of
50 pg/ml anti-IIA0 (SXCI) anti-
body (O) or an isotype control
Q5/D) (0) . Mean fluorescence in-
tensities werecalculated from 3,000
cells .
Figure 2 .
￿
IIAO does not induce
CD23 or class IMHC antigen ex-
pression on B cells. Small splenic B
cells were cultured for 22 h alone,
with rI1T10 (200 U/ml), or with
rIIJ4 (100 U/ml) . (Irft) Small B cells
from BALB/c mice were stained
with biotinylated anti-CD23 anti-
body plus SAPE . (Right) Small B
cells from CBA/J mice were stained
with biotinylated anti-H-2Kt anti-
body plus SA-PE .
mouse spleens were cultured for various times with 30 U/ml
highly purified natural 1140 from activated D10 cells, rIIA
at 100 U/ml as a positive control, or medium alone. Via-
bility was evaluated by trypan blue exclusion throughout a
4-d culture period (Fig. 4A) . Alternatively, smallB cells were
cultured with various dilutions ofCOS7 cell-expressed mouse
rIL10 (ranging from 150 to 0.15 U/ml), affinity-purified rIL4,
ormock transfection supernatant fromCOS7 cells. Viability
was measured by MTT assay at 3 d of culture (Fig. 4 B) .
Both assays showed that coculture with IWO produced a
marked enhancement ofB cell viability. Identical results of
enhanced mouse B cell viability were obtained using affinity-
purified rIL10 expressed inE. coli (data not shown) . The level
of 11,10-enhancedB cell viability was comparable with that
obtained when B cells were cultured with IL4 (Fig. 4) . An-
tibodies to IWO or IL4 blocked the enhancedB cell viability
inducedby each specific cytokine, but not by the other cytokine(Fig . 5), suggesting that both cytokines acted independently
in this assay. No additive or synergistic effect was observed
when IIA0 and IIA were both added to the B cell cultures
(data not shown) . While IIA0 enhanced the viability of small
dense B cells, it did not induce their proliferation as evalu-
ated by [ 3H]thymidine incorporation (Fig. 6) . Similarly,
11,10 did not affect B cell proliferation induced by the poly-
clonal B cell activator, LPS (Fig. 6) .
Eject ofBCRFI Protein on Small DenseB Cells.
￿
As men-
tioned above, the sequence of IIA0 is highly homologous
to that of an EBV open reading frame designated BCRFI
(8) . Furthermore, IIr10 and BCRFI protein share the prop-
erty of suppressing cytokine synthesis by activated Th1 cells
(4, 9) . We therefore testedwhetherBCRFI protein also resem-
bled IL10 in terms of its effects on small dense B cells. BCRFI
protein expressed in COS7 cells caused a marked enhance-
ment of the in vitro viability of small dense murine B cells
(Fig. 7) . The level of viability enhancement was comparable
with that induced by human rIIr10, although both of these
stimuli were less effective than mouse 1140 in enhancing via-
bility of mouse B cells (Fig. 7) . It is not surprising that at
Figure 4 .
￿
IL10 enhances in vitro B cell viability. (A) Small dense B
cells werecultured in medium alone (EI), in partially purified D10 cell-de-
rived IIL10 (30 U/ml) (O), or in rI1T4 (100 U/ml) (" ) for various times .
Cell viability was determined by trypan blue exclusion. (B) Small dense
B cells were cultured for 3 d in various dilutions ofCOS7 cell-expressed
mouse r11T10 starting at 150 U/ml (" ), in mock supernatant added at
identical dilutions (0), or in various dilutions ofrIIA starting at 100 U/ml
(O) . Cell viability was measured by MTT assay. The OD readings are
proportional to the number of viable cells.
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Figure 3 .
￿
Effects of IL4 and IIL
10 on class IIMHC antigenexpres-
sion on B cells from XID mice.
Small splenic B cells from defective
male or normal female (CBA/N x
DBA/2) F1 mice were cultured for
22 h either alone, withr11 .10 (200
U/ml), or with rIIA (100 U/ml) .
a functional level BCRFI is more closely related to human
I1r10 than to mouse 11710, since BCRFI and human IL10
are both evolved to act on human cells and BCRFI shows
a higher degree ofhomology to human IIr10 than to mouse
IIA0 (12) . The results shown in Fig . 7 indicate that com-
parable amounts ofeach stimulus were effective at enhancing
B cell viability. The maximal responses were obtained with
50 U/ml mouse IIA0, human IMO, or BCRFI, with units
in each case referring to their respective activities in themu-
rine cytokine synthesis inhibition assay (4) .
In contrast, quantities ofBCRFI protein varying from 25
to 250 U/ml did not significantly alterB cell class II antigen
expression when compared with B cells cultured in COS7
mock supernatants ormedium alone (Fig. 8 C) . Both mouse
andhumanIWO within that concentration range were capable
of maximal upregulation of B cell class II antigen expression
(Fig. 8, A and B) . Thus, BCRFI appeared capable of medi-
ating only one of the two B cell stimulatory properties of
IIA0 described in this report . This conclusion is supported
by results obtained in multiple experiments, using several
preparations of BBCRFI .
Figure 5.
￿
11,10 and IL4 enhance in vitro B cell viability independently.
Small splenic B cellsfrom BALB/c mice wereculturedfor3 d with various
concentrations of 11,10 or IIA . (A) Cells were cultured in affinity-purified
E. coli-expressed rIL10 (O),11,10 plus 10 kg/ml anti-I1,10 antibodySXCJ
(" ), IIA0 plus 10 Rg/ml anti-114 antibody 11B11 (A), or IMO plus 10
ug/ml SXC .1 isotype control antibodyJ5/D (A) . (B) Cells werecultured
in rIL4 (O), IL4 plus 10 pg/ml 11B11 ("), HA plus 10 NAg/ml SXC1
(A), or IL4 plus 10 Wg/ml 1IB11 isotype control antibody GL113 (A).co
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Figure 6.
￿
11,10 does not induce proliferation ofsmall denseB cells. Small
denseB cells werecultured for3d at variouscell concentrations in medium
alone (O), in amity-purified E . coli-expressed mouseHMO (50 U/ml)
("), in LPS (50 ug/ml) (p), or in LPS (50 ug/ml) plus 11710 (50U/ml)
(/). Cell proliferation was measured by [3H]thymidine incorporation
(cpm) .
This report identifies IIAO as a novel B cell stimulatory
factor. Highly purified natural or rIL10 can upregulate class
II MHC antigen expression and enhance in vitro viability
of small dense splenicB cells from unstimulated mice. Previous
studies haveshown that both ofthese activities are also medi-
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ated by IL4 (16, 19-22) . We believe, however, that IL10 and
IL4 induce theseB cell stimulatory activities by independent
mechanisms. Anti-IIA0 antibodies blocked 1140- but not
111,4-enhanced B cell viability and vice versa . Similarly, while
both IIAO and IL4 mediate upregulation of class IIMHC
antigen expression on restingB cells, only the latter cytokine
upregulates CD23 expression on small dense B cells (Fig . 2 ;
references 22-24) . These data argue against the possibility
that IMO-mediated upregulation ofB cell class IIMHC an-
tigen expression is due to endogenously generated IL4 . The
effects of 11,4 and IIAO on upregulating class IIMHC an-
tigen expression are further distinguished by our experiments
using the immunodeficient XID gene-bearing mice . The
results showed that XID B cells upregulate class II antigen
expression after stimulation with IL4, but not IWO . One
possible explanation for the unresponsiveness ofXIDB cells
to IIAO is that they may lack functional IL10 receptor(s) or
associated signal-transducing molecules . Alternatively, it is
possible that the observed induction of class II antigen ex-
pression on the majority of splenic B cells (Figs . 1 and 3)
is critically dependent on the presence of Ly-1 + B cells, a nu-
merically small subpopulation ofnormal splenicB cells, which
are absent from XID mice (25) . Experiments to evaluate these
possibilities are in progress. The lack of class II MHC an-
tigen induction on XID B cells suggests a possible role for
IIAO in thymus-independent type II antigen responsiveness
and/or expansion of Ly-1+ B cells, processes which are
known to be deficient in XID mice (25, 26) .
Figure 7 .
￿
Effect of BCRFI protein
on in vitroB cell viability. Small dense
B cells were cultured for3 d in COS7
cell-expressedmouse rIIr10 ("), human
rlIr10 ("), BCRFI (/), or mock su-
pernatant from COS7 cells (O) . Cell
viability was evaluated by MTT assay.
Figure 8 .
￿
Effect of BCRFI on
class IIMHC antigen expression on
small dense B cells. Splenic B cells
from BALB/c mice were cultured
for 22 h alone, or with 100 U/ml
ofCOS7 cell-expressed mouse rII,
10,human rII,10, BCRFI, or mock
supernatant of same dilutions.This study focuses on the ability of ID10 to directly stimulate
small dense B cells. Separate studies have previously identified
three factors capable of directly stimulating small dense B
cells: IL4 (19, 20), BCAF (27), and TRF2 (28). The latter
two factors have not been purified to date and so their pos-
sibleidentity with 1140 cannot be excluded. Indeed, BCAF
resembles IL10, in terms of inducing class II MHC antigens,
but not CD23 on small dense B cells (27), and TRF2 has
been shown to be inactive on XID B cells (28). While other
properties would appear to distinguish these factors from IIL10,
e.g., their ability to induce cell division and/or Ig secretion
by resting B cells, it must be recognized that in the absence
of purification or cloning, such responses may reflect syner-
gisms between multiple biologically active molecules.
This study also extends our understanding of the mecha-
nisms that regulate classII antigen expression on APC, with
IIrl0joining a group ofcytokines that were previously shown
to regulate class II expression on different cell types (19, 20,
29-31). An interesting picture concerning the interaction of
Th cells and APC is beginning to emerge from these collec-
tive studies. IFN-y, a specific product of Thl cells (5), up-
regulates class II antigens on macrophages (30-32), but not
on B cells (33) and suppresses IIA-induced classII upregula-
tion on B cells (33, 34). Conversely, IL10 and/or IIA, specific
products of Th2 cells (4, 5), upregulate class II antigens on
B cells (19, 20; this study) with little or no such effect on
IFN-y-activated macrophages (reference20; Fiorentino, D. F.,
A. Zlotnik, P. Vieira, T R. Mosmann, M. Howard, K. W
Moore, and A. O'Garra, manuscript submitted for publica-
tion), and suppress production of IFN-y (4), a major acti-
vator of macrophage antigen-presenting function (30, 31) .
Thus, it would appear that a product of Thl cells favors an-
tigen presentation by macrophages, and products of Th2 cells
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